These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 19519447)

  • 21. Interleukin-6: A Masterplayer in the Cytokine Network.
    Uciechowski P; Dempke WCM
    Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease.
    Schumertl T; Lokau J; Rose-John S; Garbers C
    Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119143. PubMed ID: 34626681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of interleukin-6 signaling in nervous tissue.
    Rothaug M; Becker-Pauly C; Rose-John S
    Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1218-27. PubMed ID: 27016501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blocking only the bad side of IL-6 in inflammation and cancer.
    Rose-John S
    Cytokine; 2021 Dec; 148():155690. PubMed ID: 34474215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.
    Chalaris A; Garbers C; Rabe B; Rose-John S; Scheller J
    Eur J Cell Biol; 2011; 90(6-7):484-94. PubMed ID: 21145125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting Interleukin-6 Classic and Trans-signaling in Inflammation and Cancer.
    Garbers C; Rose-John S
    Methods Mol Biol; 2023; 2691():207-224. PubMed ID: 37355548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-6 transsignaling: the in vivo consequences.
    Jones SA; Richards PJ; Scheller J; Rose-John S
    J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-6--a key regulator of colorectal cancer development.
    Waldner MJ; Foersch S; Neurath MF
    Int J Biol Sci; 2012; 8(9):1248-53. PubMed ID: 23136553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.
    Kallen KJ
    Biochim Biophys Acta; 2002 Nov; 1592(3):323-43. PubMed ID: 12421676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing.
    Ebihara N; Matsuda A; Nakamura S; Matsuda H; Murakami A
    Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):8549-57. PubMed ID: 21989726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
    Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
    Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The regenerative activity of interleukin-6.
    Galun E; Rose-John S
    Methods Mol Biol; 2013; 982():59-77. PubMed ID: 23456862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of blockade of peripheral interleukin-6 trans-signaling on hippocampus-dependent and independent memory in mice.
    Braun O; Dewitz C; Möller-Hackbarth K; Scheller J; Schiffelholz T; Baier PC; Rose-John S
    J Interferon Cytokine Res; 2013 May; 33(5):254-60. PubMed ID: 23215755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling.
    Malchow S; Thaiss W; Jänner N; Waetzig GH; Gewiese-Rabsch J; Garbers C; Yamamoto K; Rose-John S; Scheller J
    Biochim Biophys Acta; 2011 Mar; 1812(3):290-301. PubMed ID: 21130161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases.
    Nikolaus S; Waetzig GH; Butzin S; Ziolkiewicz M; Al-Massad N; Thieme F; Lövgren U; Rasmussen BB; Reinheimer TM; Seegert D; Rosenstiel P; Szymczak S; Schreiber S
    Int J Colorectal Dis; 2018 Jul; 33(7):927-936. PubMed ID: 29748708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
    Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
    J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation.
    Lokau J; Agthe M; Garbers C
    Mediators Inflamm; 2016; 2016():1785021. PubMed ID: 27493449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?
    Maes M; Anderson G; Kubera M; Berk M
    Expert Opin Ther Targets; 2014 May; 18(5):495-512. PubMed ID: 24548241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
    Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
    Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting IL-6 trans-signalling: past, present and future prospects.
    Rose-John S; Jenkins BJ; Garbers C; Moll JM; Scheller J
    Nat Rev Immunol; 2023 Oct; 23(10):666-681. PubMed ID: 37069261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.